CABA * logo

Cabaletta Bio BMV:CABA * Stock Report

Last Price

Mex$71.76

Market Cap

Mex$3.9b

7D

0%

1Y

n/a

Updated

05 Nov, 2024

Data

Company Financials +

CABA * Stock Overview

A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. More details

CABA * fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Cabaletta Bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cabaletta Bio
Historical stock prices
Current Share PriceUS$71.76
52 Week HighUS$418.23
52 Week LowUS$71.76
Beta2.39
1 Month Change0%
3 Month Change-45.22%
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-76.94%

Recent News & Updates

Recent updates

Shareholder Returns

CABA *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how CABA * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how CABA * performed against the MX Market.

Price Volatility

Is CABA *'s price volatile compared to industry and market?
CABA * volatility
CABA * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: CABA *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine CABA *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017137Steven Nichtbergerwww.cabalettabio.com

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.

Cabaletta Bio, Inc. Fundamentals Summary

How do Cabaletta Bio's earnings and revenue compare to its market cap?
CABA * fundamental statistics
Market capMex$3.93b
Earnings (TTM)-Mex$1.81b
Revenue (TTM)n/a

0.0x

P/S Ratio

-2.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CABA * income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$89.98m
Earnings-US$89.98m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.84
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CABA * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/05 03:44
End of Day Share Price 2024/08/08 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cabaletta Bio, Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joshua SchimmerCantor Fitzgerald & Co.
Samantha Lynn SemenkowCitigroup Inc
Joshua SchimmerEvercore ISI